Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00647400

Adalimumab in Adult Japanese Subjects With Psoriasis

A Multicenter Open-Label Continuation Study of the Long-term Safety and Efficacy of Adalimumab (D2E7) in Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis

Sponsor: Abbott

Conditions Psoriasis

Interventions adalimumab

Updated 8 times since 2017 Last updated: Apr 1, 2011 Started: Apr 30, 2006 Primary completion: Sep 30, 2007 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Psoriasis and is currently completed. Abbott leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2_PHASE3

▶ Show 3 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
Abbott Japan Co.,Ltd
Eisai Co., Ltd.

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bunkyō City, Japan , Chiyoda-ku, Japan , Fukuoka, Japan , Fukushima, Japan , Gifu, Japan , Hamamatsu, Japan , Hiroshima, Japan , Hokkaido, Japan , Ishikawa, Japan , Itabashi-ku, Japan and 26 more locations